Two years after a refuse-to-file, Y-mAbs lands an FDA adcomm for its 2nd neuroblastoma treatment

Zachary Brennan

Senior Editor

Y-mAbs Therapeutics is looking to capitalize on a second chance at winning approval for its potential treatment of pediatric neuroblastoma with CNS/cerebrospinal fluid cancer as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two years after a refuse-to-file, Y-mAbs lands an FDA adcomm for its 2nd neuroblastoma treatment

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Two years af­ter a refuse-to-file, Y-mAbs lands an FDA ad­comm for its 2nd neu­rob­las­toma treat­ment

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Two years after a refuse-to-file, Y-mAbs lands an FDA adcomm for its 2nd neuroblastoma treatment